Valuation: Ibio Inc

Market Cap 64.95M 58.03M 54.14M 49.18M 92.62M 6.28B 93.31M 651M 254M 3.2B 244M 239M 10.27B P/E 2027 *
-2.56x
P/E 2028 * -1.68x
Enterprise Value 64.95M 58.03M 54.14M 49.18M 92.62M 6.28B 93.31M 651M 254M 3.2B 244M 239M 10.27B EV / Sales 2027 *
2,598x
EV / Sales 2028 * 3,248x
Free-Float
98.68%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Ibio Inc

Manager TitleAgeSince
Chief Executive Officer 56 2023-01-19
Director of Finance/CFO 47 2023-02-12
Chief Tech/Sci/R&D Officer 59 2026-07-30
Director TitleAgeSince
Director/Board Member 53 2020-10-13
Director/Board Member 64 2020-10-13
Director/Board Member 56 2024-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-9.77%+5.96% - - 64.95M
+4.16%+4.16%+49.37%+94.17% 74.68B
-15.48%-15.78%+3.14%+51.78% 58.7B
-1.21%+1.64%+4.59%+32.82% 48.36B
+0.50%-2.14%+331.33%+702.20% 43.05B
-0.72%-3.99%+28.50%+29.94% 42.48B
+0.34%-0.52%+6.56%+109.35% 41.39B
-0.11%+1.96%+9.19%+52.66% 31.29B
-0.50%-3.10%-10.19%-14.35% 23.93B
-3.32%-10.86%-37.32%+316.28% 22.22B
Average -2.61%-2.18%+42.80%+152.76% 42.9B
Weighted average by Cap. -1.92%-1.56%+49.35%+145.09%

Financials

2027 *2028 *
Net sales 25K 22.34K 20.84K 18.93K 35.65K 2.42M 35.92K 250K 97.84K 1.23M 93.86K 91.82K 3.95M 20K 17.87K 16.67K 15.14K 28.52K 1.93M 28.73K 200K 78.27K 984K 75.08K 73.46K 3.16M
Net income -50.32M -44.96M -41.94M -38.1M -71.75M -4.87B -72.29M -504M -197M -2.48B -189M -185M -7.96B -87.99M -78.62M -73.35M -66.62M -125M -8.51B -126M -881M -344M -4.33B -330M -323M -13.92B
Net Debt - -
Logo Ibio Inc
iBio, Inc. is a biotech company leveraging artificial intelligence and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. It has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Ibio Inc